Pilot trial of interleukin-2 with granulocyte colony Stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: Expansion of immune effectors within the stem-cell graft and post-stem-cell infusion

Journal of Clinical Oncology

Volumn 19, Issue 3, 2001, Pages 634-644

  Sosman, J A ^a   Stiff, P ^a   Moss, S M ^a   Sorokin, P ^a   Martone, B ^a   Bayer, R ^a   Van Besien, K ^a   Devine, S ^a   Stock, W ^a   Peace, D ^a   Chen, Y ^a   Long, C ^a   Gustin, D ^a   Viana, M ^a   Hoffman, R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER IMMUNOTHERAPY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; NAUSEA; PRIORITY JOURNAL; VERTIGO; VOMITING;

EID: 0035254840     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.3.634     Document Type: Article

References (49)

1. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer
2. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
3. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy
4. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer
5. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13
6. Randomised, controlled trial of high dose chemotherapy (HD-CNVp) vs. standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer
7. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy
8. Phase III randomized trial of high-dose chemotherapy(HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia Intergroup Study (PBT-01)
9. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver
10. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer
11. Hematopoietic growth factors for graft failure after bone marrow transplantation: A randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF
12. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy
13. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation
14. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
15. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy
16. CD16-, CD56+ natural killer cells after bone marrow transplantation
17. T-cell ontogeny after autologous bone marrow transplantation: Failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4- and CD8+ cells even in the presence of exogenous IL-2
18. Cytomegalovirus specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants
19. Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections
20. Adoptive immunotherapy with high-dose interleukin-2: Kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony-stimulating factor level
21. Myelostimulatory activity of recombinant human interleukin- 2 in mice
22. In vivo induction of the lymphokine-activated killer phenomenon: Interleukin-2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin- 2
23. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin- 2 and LAK cell therapy
24. Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin- 2
25. In vivo administration of purified human interleukin-2 to patients with cancer: Development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration
26. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer
27. Clinical and immunological effects of recombinant interleukin- 2 given by repetitive weekly cycles to patients with cancer
28. Low dose subcutaneous interleukin- 2 after autologous transplantation generates sustained in vivo natural killer cell activity
29. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation
30. Interleukin- 2 activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo
31. Activated natural killer cells and interleukin- 2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice
32. Adherent lymphokine activated killer cells suppress autologous human normal bone marrow progenitors
33. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells
34. Granulocyte colony stimulating factor to prevent the progression of systematic nonresponsiveness in systematic inflammatory response syndrome and sepsis
35. + progenitor cells in high-risk breast cancer patients (PTS): Higher yield by splitting the dose
36. Interleukin- 2 therapy after autologous bone marrow transplantation for hematologic malignancies
37. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate post-transplant period
38. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients post-autologous marrow or stem cell transplantation
39. Interleukin-2-mobilized autologous peripheral blood stem cell transplantation followed by interleukin-2 maintenance for the treatment of acute myelogenous leukemia in first complete remission
40. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation
41. Hematopoietic potential of IL-2-cultured peripheral blood stem cells from breast cancer patients
42. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer
43. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: Investigation of dose level with clinical correlates
44. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma
45. Allogeneic peripheral blood progenitor-cell transplantation for poor-risk patients with meta-static breast cancer
46. Feasibility of immunotherapy relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
47. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells
48. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
49. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines